Literature DB >> 25716331

The Design of Nanostructured Metronidazole-Loaded HPC/Oxide Xerogel Composites: Influence of the Formulation Parameters on In Vitro Characterisation.

Katarzyna Czarnobaj1.   

Abstract

In this study, oxide and polymer/oxide xerogels with metronidazole were prepared and examined as carriers of drug for the local application to the bone. The nanoporous SiO2-CaO-P2O5 and HPC-SiO2-CaO-P2O5 xerogel materials with different amounts of the polymer [hydroxypropyl cellulose (HPC)] were prepared using the sol-gel technology, and their physicochemical properties were characterised with respect to chemical structure [by Fourier transform infrared spectroscopy (FTIR)], porosity and the specific surface area of solids (BET), crystallinity [by X-ray powder diffraction (XRD)], morphology [by scanning electron microscope (SEM)] and the in vitro release of the metronidazole over time (by UV-vis spectroscopy, in the ultraviolet light region). HPC-modified oxide xerogels as the carriers of drug showed slower release of metronidazole, due to the structure and stronger interactions with drug as compared with the pure oxide xerogel. Kinetic analysis indicated diffusional mechanism of drug release from all xerogel carriers. HPC addition to the oxide material resulted in a decrease in the porosity and improved the bioactive properties of xerogels. Obtained results for xerogel composites suggest that the metronidazole-loaded xerogels could be attractive candidates for local delivery systems particularly to a bone.

Entities:  

Keywords:  drug delivery systems; nanostructured composites; porous materials

Mesh:

Substances:

Year:  2015        PMID: 25716331      PMCID: PMC4674639          DOI: 10.1208/s12249-015-0310-4

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  15 in total

Review 1.  Modeling and comparison of dissolution profiles.

Authors:  P Costa; J M Sousa Lobo
Journal:  Eur J Pharm Sci       Date:  2001-05       Impact factor: 4.384

Review 2.  How useful is SBF in predicting in vivo bone bioactivity?

Authors:  Tadashi Kokubo; Hiroaki Takadama
Journal:  Biomaterials       Date:  2006-01-31       Impact factor: 12.479

3.  Analysis of Fickian and non-Fickian drug release from polymers.

Authors:  N A Peppas
Journal:  Pharm Acta Helv       Date:  1985

4.  Alkyl-substituted silica gel as a carrier in the controlled release of dexmedetomidine.

Authors:  P Kortesuo; M Ahola; M Kangas; T Leino; S Laakso; L Vuorilehto; A Yli-Urpo; J Kiesvaara; M Marvola
Journal:  J Control Release       Date:  2001-10-19       Impact factor: 9.776

5.  Silica xerogel carrier material for controlled release of toremifene citrate.

Authors:  M Ahola; P Kortesuo; I Kangasniemi; J Kiesvaara; A Yli-Urpo
Journal:  Int J Pharm       Date:  2000-02-15       Impact factor: 5.875

6.  Sol-gel processing of drug delivery materials and release kinetics.

Authors:  F De Gaetano; L Ambrosio; M G Raucci; A Marotta; M Catauro
Journal:  J Mater Sci Mater Med       Date:  2005-03       Impact factor: 3.896

7.  Solutions able to reproduce in vivo surface-structure changes in bioactive glass-ceramic A-W.

Authors:  T Kokubo; H Kushitani; S Sakka; T Kitsugi; T Yamamuro
Journal:  J Biomed Mater Res       Date:  1990-06

8.  In vitro bioactivity and degradation behavior of silica xerogels intended as controlled release materials.

Authors:  Shula Radin; Sylvie Falaize; Mark H Lee; Paul Ducheyne
Journal:  Biomaterials       Date:  2002-08       Impact factor: 12.479

9.  Sol-gel processed porous silica carriers for the controlled release of diclofenac diethylamine.

Authors:  Katarzyna Czarnobaj; Joanna Czarnobaj
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2008-10       Impact factor: 3.368

10.  Bioactive glass as a drug delivery system of tetracycline and tetracycline associated with beta-cyclodextrin.

Authors:  Z R Domingues; M E Cortés; T A Gomes; H F Diniz; C S Freitas; J B Gomes; A M C Faria; R D Sinisterra
Journal:  Biomaterials       Date:  2004-01       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.